ArielaNoyMD

PubMed

• Matched control analysis suggests R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared to R-CHOP.
  Bantilan, K., Smith, A., Maurer, M., Teruya-Feldstein, J., Matasar, M., Moskowitz, A., Straus, D., Noy, A., Palomba, M., Horwitz, S., Hamlin, P., Portlock, C., Cerhan,...> ;Blood Advances. 2024 Jan 25
• Correction to: Factors Affecting Diagnostic Yield of Lesional Bone Biopsy in Hematologic Malignancy Patients.
  Cooke, T., Petre, E., Gangai, N., Maybody, M., Aly, A., Santos, E., Noy, A., Chan, A., Lis, E., Cornelis, F., Moussa, A.> ;Cardiovascular and Interventional Radiology. 2024 Jan 1
• Factors Affecting Diagnostic Yield of Lesional Bone Biopsy in Hematologic Malignancy Patients.
  Timothy M Cooke, Majid Maybody, Ahmed K Aly, Elena N Petre, Ernesto Santos, Ariela Noy, Alexander Y Chan, Eric Lis, Natalie Gangai, Francois H Cornelis, Amgad M Moussa> ;Cardiovascular and Interventional Radiology. 2024 Jan 1
• Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.
  Robert Stuver, Ariela Noy, Santosha A Vardhana, Andrew D Zelenetz, Alison J Moskowitz> ;British Journal of Haematology. 2024 Feb 1
• Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes.
  Paola Ghione, Salma Ahsanuddin, Efrat Luttwak, Sabela Bobillo Varela, Reiko Nakajima, Laure Michaud, Kanika Gupta, Anastasia Navitski, David Straus, M Lia Palomba, Ali...> ;Haematologica. 2024 Jan 1
• 2 citations
  Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.
  Paul G Rubinstein, Page C Moore, Milan Bimali, Jeanette Y Lee, Michelle A Rudek, Amy Chadburn, Lee Ratner, David H Henry, Ethel Cesarman, Camille E DeMarco, Dominique ...> ;The Lancet. Haematology. 2023 Aug 1
• Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R.
  Rahul Lakhotia, Kieron Dunleavy, Jeremy S Abramson, Brian K Link, Bayard L Powell, Christopher Melani, Andrea N Lucas, Seth M Steinberg, Jonathan W Friedberg, Brad S K...> ;Blood Advances. 2023 Sep 26
• The efficacy of tixagevimab-cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma S...
  Efrat Luttwak, Ariela Noy, Venkatraman Seshan, Larry A Saltzman, Lee M Greenberger> ;Leukemia & Lymphoma. 2023 Oct 1
• 5 citations
  Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy pat...
  Justin C Laracy, Judy Yan, Samantha N Steiger, Carrie A Tan, Nina Cohen, Elizabeth V Robilotti, Jerome Fender, Sara Cohen, Neha Korde, Melissa Lee-Teh, Ariela Noy, Jos...> ;Haematologica. 2023 Nov 1
• 1 citations
  Retrospective characterization of nodal marginal zone lymphoma.
  Robert Stuver, Esther Drill, David Qualls, Michelle Okwali, Connie Lee Batlevi, Philip C Caron, Ahmet Dogan, Zachary D Epstein-Peterson, Lorenzo Falchi, Paul A Hamlin,...> ;Blood Advances. 2023 Sep 12
• 3 citations
  TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
  William T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, Alison J Moskowitz, Robert N Stuver, Catherine R Maccaro, Natasha Galasso, Tiffany Chang, Niloufer Khan...> ;Blood Advances. 2023 Sep 12
• 2 citations
  Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting.
  Serena Zheng, Kanika Gupta, Piyush Goyal, Reiko Nakajima, Laure Michaud, Connie Lee Batlevi, Paul A Hamlin, Steven Horwitz, Anita Kumar, Matthew J Matasar, Alison J Mo...> ;Cancers. 2023 Mar 14
• 20 citations
  Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma.
  Thomas, N., Dreval, K., Gerhard, D., Hilton, L., Abramson, J., Ambinder, R., Barta, S., Bartlett, N., Bethony, J., Bhatia, K., Bowen, J., Bryan, A., Cesarman, E., Casp...> ;Blood. 2023 Feb 23
• 3 citations
  Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma withormutations: an open label phase II study.
  David Qualls, Ariela Noy, David Straus, Matthew Matasar, Craig Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Ba...> ;Leukemia & Lymphoma. 2023 Mar 1
• 1 citations
  Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era.
  David Qualls, Brandon S Imber, Michelle Okwali, Paul A Hamlin, Anita Kumar, Oscar B Lahoud, Matthew J Matasar, Ariela Noy, Colette Owens, Andrew D Zelenetz, Victoria S...> ;British Journal of Haematology. 2023 Feb 1
• 1 citations
  Predictors of survival in patients with MALT lymphoma: a retrospective, case-control study.
  Shunan Qi, Xin Liu, Ariela Noy, Jisun Lee, Sewit Teckie, Carla Hajj, Erel Joffe, Brandon S Imber, Joachim Yahalom> ;Blood Advances. 2023 Apr 25
• 4 citations
  Predictors of Major Hemorrhage After Spleen Core Biopsy in Cancer Patients.
  Henry Kunin, N Ari Wijetunga, Joseph P Erinjeri, Ariela Noy, Amy R Deipolyi> ;Journal of Vascular and Interventional Radiology. 2022 Sep 1
• Discordant SARS-CoV-2 spike protein receptor binding domain IgG and neutralization after B-cell depletion.
  Ariela Noy, Santosha A Vardhana> ;Haematologica. 2022 Dec 1
• 60 citations
  Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
  Robert Stuver, Gunjan L Shah, Neha S Korde, Lindsey E Roeker, Anthony R Mato, Connie L Batlevi, David J Chung, Sital Doddi, Lorenzo Falchi, Boglarka Gyurkocza, Audrey ...> ;Cancer Cell. 2022 Jun 13
• 1 citations
  Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.
  Fushen Sha, Michelle Okwali, Anna Alperovich, Philip C Caron, Lorenzo Falchi, Audrey Hamilton, Paul A Hamlin, Steven M Horwitz, Erel Joffe, Niloufer Khan, Anita Kumar,...> ;Blood Cancer Journal. 2022 Feb 10
• 38 citations
  Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or ...
  Jacob D. Soumerai, Anthony R. Mato, Ahmet Dogan, Venkatraman E. Seshan, Erel Joffe, Kelsey Flaherty, Jason Carter, Ephraim P. Hochberg, Jeffrey A. Barnes, Audrey Hamil...> ;The Lancet. Haematology. 2021 Dec 1
• 2 citations
  Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience.
  Terry K. Pak, Brianne N. Dixon, Michael J Buege, Phuong H. Dao, Megan H. Leary, Joy C. Jarrett, Tara A. Duggan, Philip Caron, Lorenzo Falchi, Paul A. Hamlin, Audrey Ha...> ;Leukemia & Lymphoma. 2021 Nov 16
• 53 citations
  Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
  Alison J. Moskowitz, Paola Ghione, Eric D. Jacobsen, Jia Ruan, Jonathan H. Schatz, Sarah J. Noor, Patricia L. Myskowski, Santosha A. Vardhana, Nivetha Ganesan, Helen H...> ;Blood. 2021 Oct 19
• 1 citations
  Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial
  Polina Shindiapina, Maciej Pietrzak, Michal Seweryn, Eric McLaughlin, Xiaoli Zhang, Mat Makowski, Elshafa H. Ahmed, Sarah Schlotter, Rebecca Pearson, Rhonda Kitzler, A...> ;Frontiers in Immunology. 2021 Sep 3
• 5 citations
  Prephase rituximab/prednisone therapy and aging-related, pro-inflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
  Richard J. Lin, Colette Owens, Esther Drill, Augustine Iannotta, Mayan Oliveros, Dylan L Schick, Ariela Noy, John F. Gerecitano, Pamela Drullinsky, Philip Caron, Anita...> ;Haematologica. 2021 Jul 22
• Join now to see all

Abstracts/Posters

• Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 107
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803...
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatm...
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all